

To: [redacted] @bmg.bund.de]; [redacted]
[redacted] @pm.gouv.fr]; [redacted] @pm.gouv.fr]; [redacted] @minvws.nl]; [redacted] @minvws.nl];
[redacted] @minvws.nl]; [redacted] @minvws.nl]; [redacted] @unicatt.it]; [redacted] @unicatt.it];
[redacted] @minvws.nl]; [redacted] @minvws.nl]; [redacted] @igf.finances.gouv.fr]; [redacted] @igf.finances.gouv.fr];
Cc: [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de];
[redacted] @bmg.bund.de]; [redacted] @bmg.bund.de]; Müller; [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de];
From: [redacted]
Sent: Mon 6/8/2020 3:52:03 PM
Subject: R: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
Received: Mon 6/8/2020 3:52:07 PM

Dear colleagues,
we agree with you about the point 11 as a point of big concern to be clarified.
The tomorrow ministerial meeting would deal with this issue
Kind regards

[redacted]



[redacted]

Ministry of Health – Italy
Viale G. Ribotta, 5 – ROMA
Tel. [redacted]
Mo [redacted]

[Large redacted area containing multiple lines of redacted text and a signature block]

2 - 3

5.1.2a